Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Benzinga's Top Upgrades
Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q3 2015 Update (Seeking Alpha)
Related IPXL
Impax Receives FDA Approval for Generic Version of Intuniv Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg
Janet S. Vergis Appointed to Impax Laboratories Board of Directors
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity (GuruFocus)

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters